Inhibitors of factor VIII and IX
1995; Wiley; Volume: 1; Issue: S1 Linguagem: Inglês
10.1111/j.1365-2516.1995.tb00108.x
ISSN1365-2516
Autores Tópico(s)Hemostasis and retained surgical items
ResumoHaemophiliaVolume 1, Issue S1 p. 35-39 Inhibitors of factor VIII and IX DOREEN B. BRETTLER, DOREEN B. BRETTLER New England Hemophilia Center, Worcester, Massachusetts, USASearch for more papers by this author DOREEN B. BRETTLER, DOREEN B. BRETTLER New England Hemophilia Center, Worcester, Massachusetts, USASearch for more papers by this author First published: January 1995 https://doi.org/10.1111/j.1365-2516.1995.tb00108.xCitations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Lusher JM.. Factor VIII inhibitors: etiology, characterization, natural history and management. Ann NY Acad Sci, 1987; 509: 89–102. 2 Addiego J., Kasper C., Abildgaard C., et al. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet, 1993; 342: 462–464. 3 Ehrneforth S., Kruez W., Scharrer I., et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 1992; 339: 594–598. 4 Lusher LM., Salzman PM. and the Monoclate Study Group.. Viral safety and inhibitor development associated with factor VIII ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII: C concentrates. Semin Hemat, 1990; 27: 1–7. 5 Lusher JM., Arkin S., Abildgaard CF., Schwartz RS., and the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia. N Engl J Med, 1993; 328: 453–459. 6 Bray GL., Gomperts ED., Courter S., et al. and the Recombinant Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood, 1994; 83: 2428–2435. 7 Peerlinck K., Arnout J., Gilles JG., Saint-Remy JM., Vermeyllen J.. A higher than expected incidence of factor VIII inhibitors in multitransfused hemophilia A patients treated with intermediate purity pasteurized factor VIII concentrate. Thrombos Haemostas, 1993; 69: 115–119. 8 Shapiro SS.. Genetic predisposition to inhibitor formation. Prog Clin Biol Res, 1984; 150: 45–55. 9 Lippert LE., Fisher L., Schook LB.. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thrombos Hemostas, 1990; 64: 564–568. 10 Reisner HM., Levin LG.. Immunogenetics of human immune response to factor VIII. Presented at 2nd International Symposium on Inhibitors to Coagulation Factors, Chapel Hill , N.C. , 1993. 11 Scandella D., Mattingly M., de Graff S., et al. The localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood, 1989; 74: 1618–1626. 12 Millar DS., Steinbrecher RA., Whittmore D., et al. The molecular genetic basis of hemophilia A; characterization of six partial deletions in the factor VIII genet. Human Genet, 1990; 86: 219–224. 13 Kasper CK., Aledort LM., Counts RB., et al. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh, 1975; 34: 869–872. 14 Lusher JM., Shapiro SS., Palascek JE., et al. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII. N Engl J Med, 1980; 303: 421–425. 15 Sjamsoedin LJ., Heijnen L., Mauser-Bunschoten EP., et al. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double blind clinical trial. N Engl J Med, 1981; 305: 717–721. 16 Lusher JM., Blatt PM., Penner JA., et al. Autoplex vs. proplex: A double controlled double blind study of effectiveness in acute hemarthrosis in hemophiliacs with inhibitors to factor VIII. Blood, 1983; 62: 1135–1138. 17 Chavin SI., Siegel DM., Rocco TA., Jr., Olson HP.. Acute myocardial during treatment with an activated prothrombin complex concentrate in a patient with FVIII deficiency and FVIII inhibitor. Am J Med 1988; 85: 245–249. 18 Agrawal BL., Zelkowitz L., Hletko P.. Acute myocardial infarction in a young hemophiliac patient during therapy with factor IX concentrate and epsilon aminocaproic acid. J Pediatr, 1981; 98: 931–933. 19 Blatt PM., White GC., McMillan CW., Robert HR.. Treatment of anti factor VIII antibodies. Thrombos Haemostas, 1977; 38: 514–523. 20 Nilsson IM., Jonsson S., Sundquist S., Ahlberg A., Bergentz SE.. A procedure for removing high titer antibodies by extra-corporeal protein A sepharose adsorption in hemophilia. Blood, 1981; 58: 38–44. 21 Kernoff, PB., Thomas ND., Lilley PA., et al. Clinical experience with polyecectroplyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood, 1984; 63: 31–41. 22 Brettler, DB., Forsberg, AD., Levine, PH., et al. The use of porcine factor VIII concentrate in the treatment of patients with inhibitor antibodies to factor VIII: C. A multicentre US experience. Arch Intern Med, 1989; 149: 1381–1389. 23 Gringeri A., Santoagostino E., Tradati F., Giangrande PL., Mannucci PM.. Adverse effects of treatment with porcine factor VIII. Thrombos Haemostas, 1991; 65: 245–247. 24 Hay CR., Laurian Y., Verroust F., Preston E., Kernoff PB.. Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIII: C by home therapy. Blood, 1990; 76: 882–886. 25 Hoffman M., Monroe DM., Roberts HR.. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: Implications for the therapeutic mechanism of high dose factor VIIa in hemophilia. Blood, 1994; 83: 38–42. 26 Hedner U., Kisiel W.. Use of human factor VIIA in the treatment of two hemophilia A patients with high titer inhibitors. J Clin Invest, 1983; 71: 1836–1841. 27 Hedner U., Glazer S., Pingel K., et al. Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy. Lancet, 1988; ii: 1193. 28 Ingerslev J., Feldstedt M., Petersen-Sindet S.. Control of haemostasis with recombinant factor VIIa in a patient with inhibitor to factor VIII. Lancet, 1991; 338: 831–832. 29 Macik BG., Hohnekr J., Roberts HR., Griffen AM.. Use of recombinant activated factor VII for treatment of retropharyngeal hemorrhage in a hemophilic patient with high titer inhibitor. Am J Hemat, 1989; 32: 232–234. 30 Gringeri A., Santagostino E., Mannucci PM.. Failure of recombinant activated factor VII during surgery in a hemophiliac with high titer factor VIII antibodies. Hemostasis, 1991; 21: 1–4. 31 Hyland Baxter Company. Update on recombinant tissue factor. Recombinant Factor VIII Symposium. Keystone Co., 1991. 32 Brachmann HH.. Induced immune tolerance in factor VIII inhibitor patients. Prog Clin Biol Res, 1986; 150: 181–195. 33 Van Leeuwen EF., Mauser-Bunschoten EP., Van Kijken PJ., Kok AK., Sjamsoedin-Visser EJ., Sixma JJ.. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Brit J Haemat, 1986; 64: 291–297. 34 Ewing NP., Sander NL., Deitrich SL., Kasper CK.. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. J Am Med Assoc, 1988; 259: 65–68. 35 Aznar JA., Jorquera JL., Peiro A.. Suppression of inhibitors in haemophilia with corticoids and factor VIII. Thrombos Haemostas, 1983; 49: 241–243. 36 Nilsson IM., Berntorp E., Zettervall O.. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med, 1988; 328: 947–950. 37 Mariani G.. Immune tolerance to FVIII: International Registry Data. Presented at the 2nd International Symposium on Inhibitors to Coagulation Factors, University of North Carolina, November 1993. 38 Nilsson IM., Berntorp E., Zettervall O.. Induction of split tolerance and clinical cure in high responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA, 1986; 83: 9169–9173. Citing Literature Volume1, IssueS1January 1995Pages 35-39 ReferencesRelatedInformation
Referência(s)